-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Speaker

Program: Continuing Conversations with the Speakers
Session: Continuing Conversations with the Speakers on Harnessing T cells in Therapy of Hematologic Malignancy
Sunday, December 6, 2015, 11:15 AM-12:15 PM
W303, Level 3 (Orange County Convention Center)

Michel Sadelain, MD, PhD

Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY

Disclosures: Sadelain: Juno Therapeutics: Consultancy , Equity Ownership , Other: Co-Founder, stockholder , Patents & Royalties: Licensed patents on CARs .

See more of: Continuing Conversations with the Speakers on Harnessing T cells in Therapy of Hematologic Malignancy
See more of: Continuing Conversations with the Speakers
<< Previous Presentation | Next Presentation >>